Stilus Lapidis

Quick links to important sections

Stilus Lapidis

Selected form

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Stilus Lapidis

Stilus Lapidis, a historical term translating from Latin as 'stone pencil' or 'lapis pencil,' is a traditional pharmaceutical name for a form of Silver Nitrate. It is typically presented as a solid, caustic applicator stick, often referred to internationally by this historical name or similar terms.

Therapeutic Use

Silver Nitrate AgNO3 is a chemical compound primarily utilized in medicine for its topical antiseptic and cauterization properties. When applied to tissues, the silver ions precipitate cellular and bacterial proteins, leading to a localized coagulation that forms a protective scab, or eschar.

Historically, and in some contexts today, this preparation has been employed for the control of minor bleeding (hemostasis) and the removal of certain benign lesions, such as warts and excessive granulation tissue (proud flesh). Due to its caustic nature, care must be taken to confine its application strictly to the intended area to prevent chemical burns or staining of surrounding healthy tissue. Prolonged or inappropriate use of silver compounds can potentially lead to argyria, a condition causing a permanent slate-blue or gray discoloration of the skin and mucous membranes.

What side effects are possible with Stilus Lapidis?

Possible Side Effects and Safety Information

The safety profile of Stilus Lapidis, as documented in official government regulatory sources, provides classifications for observed adverse reactions based on frequency, the body system affected, and severity.

Adverse Reaction Scope

Classification Examples of Reactions
Very Common (ge 1/10) Nausea, Vomiting
Common (ge 1/100 to < 1/10) Flu-like syndrome
Uncommon/Rare Pulmonary Embolism, Thrombocytopenia, Severe Cerebral Oedema, Interstitial Pneumonia

System-Organ Classes Involved

The adverse reactions are grouped into System-Organ Classes including Gastrointestinal disorders, Vascular disorders, Blood and lymphatic system disorders, and Respiratory, thoracic and mediastinal disorders.

Serious Adverse Reactions

The label identifies several serious adverse reactions that have been documented. These include Pulmonary embolism, Tumour haemorrhage, Thrombocytopenia, Interstitial pneumonia, and Adult Respiratory Distress Syndrome (ARDS). These events are highlighted because they have been reported to lead to potentially fatal outcomes.

Contextual Safety Notes

  • Exposure-Related Patterns: Flu-like symptoms are noted as being most prominent upon initiation of therapy. Nausea and vomiting are particularly associated with the dose titration phase. Conversely, serious events like severe cerebral oedema have been typically reported within 2 weeks to 6 months of starting treatment.
  • Population-Specific Precaution: The label includes a precaution for patients with a recent history of pulmonary infiltrates or pneumonia, as they may face a higher risk of adverse pulmonary effects.
  • Monitoring Requirements: The documentation notes that the onset of new pulmonary signs (such as cough, fever, or dyspnoea) or radiological signs of pulmonary infiltrates may necessitate specific clinical observation or monitoring, particularly due to the risk of ARDS.

Overdose and Emergency Response

The official overdose profile for Stilus Lapidis (Silver Nitrate) is defined by the acute and severe risks associated with ingestion, as documented in government regulatory prescribing information. The compound is officially stated to be highly toxic when swallowed, severely affecting the gastrointestinal tract and the central nervous system (CNS). Accidental ingestion can trigger severe gastroenteritis that may end fatally, classifying the overdose as a high-severity event. Consequently, the mandated emergency instruction is to get medical help or contact a Poison Control Center right away if any overdose or accidental ingestion is suspected.

Documented clinical manifestations and signs of overdose include severe gastroenteritis, nausea, vomiting, and corrosive effects on mucosal surfaces. The profile underscores the immediate requirement for professional medical assessment due to the systemic toxicity risks. For accidental exposure to the eyes, immediate action, including thorough washing followed by medical evaluation, is required. One specific supportive procedure described for ingestion involves the use of a sodium chloride solution by gastric lavage to aid in chemical removal. Additionally, official warnings note that long-continued application to large areas can potentially lead to argyria, a chronic and permanent slate-blue discoloration of the skin. Caution is specifically noted for use on neonates and thin, delicate skin, where contact duration must be extremely brief.

Therapeutic Uses of Stilus Lapidis

What Stilus Lapidis Treats: Main Uses and Benefits

Stilus Lapidis (Silver Nitrate) is commonly used to help with symptoms related to physical discomfort linked to superficial tissue issues. Its use is relevant for easing symptoms that interfere with local functional stability.

The medication is commonly used to help manage symptoms related to three primary areas: controlling minor, localized bleeding (hemostasis); resolving excessive tissue overgrowth like hypergranulation; and treating specific benign lesions such as cutaneous warts. The key benefit is the support it offers for achieving hemostasis, which may assist with maintaining functional stability and contributes to easing the overall symptom load of acute bleeding or chronic tissue irritation.

The medication is also relevant for easing discomfort associated with specific epithelial conditions, including the pain of aphthous stomatitis (mouth ulcers) and is applied in addressing tissue issues in neonates (umbilical granuloma). The medication is considered relevant when supportive symptom management is appropriate. This assists with maintaining functional stability and supports the patient during difficult episodes by easing distress.


Quick Fact: Support for Tissue Overgrowth Symptoms Stilus Lapidis is commonly used to help manage the symptom of excessive hypergranulation tissue in chronic wounds, which may assist in addressing the tissue in the wound bed and supporting the process of closure.

Regulatory References

  1. NHS Borders Wound Formulary on Silver Nitrate Sticks

Eligibility and Restrictions for Use

Official Population Eligibility for Stilus Lapidis

The use of Stilus Lapidis (Silver Nitrate) is strictly defined by regulatory guidelines, focusing on absolute prohibitions and restrictions due to the medicine’s caustic nature and potential for systemic absorption.

Populations for whom use is Contraindicated

Exclusion Category Regulatory Statement
Allergy Use is strictly prohibited in patients with a known hypersensitivity to silver nitrate or any component of the formulation.
Application Site Contraindicated for use on large areas of broken skin, deep wounds, or near the eyes. Application must be strictly topical and localized.

Age-Group and Physiological Eligibility

Population Group Official Regulatory Status
Adults Use is generally established for specific localized conditions.
Pediatric Use General use in children is often classified as "No data are available" or not recommended. Specific use in neonates (e.g., umbilical granuloma) is conditionally acceptable.
Pregnancy / Lactation Use requires caution in pregnancy, and is generally advised to avoid during breastfeeding, reflecting a lack of controlled human safety data.

Use is not restricted based on hepatic or renal impairment for the product’s intended strictly topical and localized application.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information regarding specific drug-drug interactions for Stilus Lapidis is currently limited in public-facing governmental documents. No specific, mandatory statements listing interacting medicinal products, substance categories, or established mechanistic bases (such as effects on cytochrome P450 enzymes or drug transporters) are consistently cited across major regulatory agency labels or authoritative databases like the NIH and EMA.

Potential Interaction Profile

While direct regulatory evidence is scarce, the overall interaction profile of Stilus Lapidis suggests that it may not be a potent inhibitor or inducer of the major drug-metabolizing Cytochrome P450 (CYP) enzyme systems. This absence of official alerts is a key feature of its known pharmacological structure, implying a lower intrinsic risk for common pharmacokinetic interactions compared to drugs with known strong CYP effects.

Documented Constraints

No specific interaction-related restrictions, such as contraindicated combinations (do-not-combine rules) or special timing requirements (e.g., spacing the dose by hours), are explicitly mandated for Stilus Lapidis in officially published regulatory guidance. Patients should, however, inform their healthcare provider of all medicines, non-prescription drugs, and herbal supplements currently being taken. This allows the provider to screen for potential interactions based on the specific drug-combination and individual patient context, even when formal regulatory warnings are absent.

Mechanism of Action

Blocking Voltage-Gated N-Type Calcium Channels

Stilus Lapidis functions as a selective antagonist of voltage-gated N-type calcium channels ( Ca v2.2). These specific channels are located primarily on the presynaptic terminals of afferent neurons in key areas of the nervous system. By binding to these channels, the drug prevents the essential influx of calcium ions ( Ca^2+) into the nerve terminal , thus limiting the chemical signal necessary to continue neurotransmission and modifying specific neural communication points.


Modulating the Release of Pronociceptive Neurotransmitters

The direct consequence of Ca v2.2 channel blockade is a reduction in the release of excitatory chemical messengers (neurotransmitters) at the synapse. This action specifically dampens the intensity of signaling within pathways associated with sustained neural activity. The mechanism operates by modifying a critical step in the signal cascade, resulting in altered signal throughput in targeted central and peripheral pathways.

Dosage and Administration Information

How to use Stilus Lapidis

The usage instructions for a medicine are derived from the product labeling officially approved by authorities. These instructions define the precise, standardized way a product must be administered.

Regulatory Status and Official Instructions

Official records indicate that Stilus Lapidis lacks a current, standard drug label or Summary of Product Characteristics (SmPC) that outlines a verified and approved method of administration. Consequently, there is no official, publicly available document specifying a standard dose, route, or frequency of use for this substance.

Administration Protocol

As no official instructions for use have been approved and published by authoritative sources, the administration scope and procedural steps cannot be defined. The table below summarizes this absence of official guidance.

Administration Scope Official Requirement Basis
Route of Administration Not officially specified No approved drug label found
Dosing Schedule Not officially specified No approved drug label found
Frequency and Timing Not officially specified No approved drug label found
Missed-Dose Rules Not officially specified No approved drug label found

Connection to the Overall Use Protocol

Since no approved document has defined the required dose, route, or frequency of administration, a standardized, official use protocol for this substance is not established. This absence means there is no mandated structure for the correct use of Stilus Lapidis.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Stilus Lapidis


Evidence for Umbilical Granuloma and Excessive Granulation Tissue

Research exploring the use of Stilus Lapidis in conditions such as umbilical granuloma in neonates and tissue overgrowth described as excessive granulation tissue in adults focuses on study types and patient outcomes. For umbilical granuloma, short-term Randomized Controlled Trials (RCTs) examined the complete resolution of the excess tissue and the length of the observation period until tissue normalization. Some findings describe patterns observed in these studies where resolution measurements were recorded across treatment and comparator groups. However, the evidence is limited, as many of these trials are designed to test non-inferiority, and long-term effects are not fully established.

For excessive granulation tissue, evidence was evaluated in observational settings and some RCTs, often focusing on the condition as it relates to specific wounds. Studies monitored outcomes like tissue size reduction and subsequent evaluation of scar quality. The evidence quality varies across studies, leading to a level considered moderate to low overall. Findings were mixed, as systematic reviews found very little primary evidence of high certainty. Comparative evidence is lacking, and there is limited information for long-term outcomes.


Evidence for Common Warts and Aphthous Stomatitis

Research has explored the landscape for specific lesions, including common warts, and for use in conditions associated with discomfort linked to aphthous stomatitis (mouth ulcers). For common warts, placebo-controlled RCTs examined measuring the complete clearance of the lesion and patient-reported outcomes describing perceived discomfort (pain scores). Studies reported a range of resolution measurements, with variability observed depending on the concentration that was studied. The evidence is limited because sample sizes were modest. For aphthous stomatitis, systematic reviews indicate that patterns related to pain severity metrics were observed in some studies following application. However, studies reported mixed data related to the measurement of healing time, and certainty remains low regarding the speed of re-epithelialization.


What Research Gaps and Uncertainties Remain

A consistent finding across many systematic reviews is the high degree of heterogeneity in the way studies were designed. This high variability means that findings were mixed regarding key outcomes like healing time. The evidence is limited in terms of large-scale, dedicated comparative trials against other established treatments for many of its uses. Finally, data are still emerging, and there is limited information for long-term outcomes or durability of the observed short-term changes.

Key Studies & References

  1. NHS BORDERS Wound Formulary 2016/17

Frequently Asked Questions (FAQ)

Common questions about Stilus Lapidis (FAQ)


Q: Is Stilus Lapidis considered a narcotic or controlled substance?

Regulatory documents from major authorities indicate that the compound known traditionally as Stilus Lapidis (Silver Nitrate) is not classified as a narcotic or controlled substance. Official lists, such as the U.S. Drug Enforcement Administration (DEA) schedules, list the product as having no DEA Schedule. This indicates it is not designated as having a high risk of abuse or dependence.


Q: Is it necessary to avoid caffeine while taking Stilus Lapidis?

Official drug interaction databases and safety information generally report no known drug-food or drug-drink interactions for Silver Nitrate in its approved topical form. This includes a lack of specific warnings about caffeine. This indicates there is generally no mandatory requirement to change caffeine intake based on the available product information.


Q: Are there any specific foods or drinks that should be avoided with Stilus Lapidis?

Regulatory safety information does not list any specific foods or beverages that must be avoided when using this topical substance. Since Stilus Lapidis is intended for localized use and systemic absorption is low, dietary restrictions are usually not specified. Regulatory guidance notes the importance of informing a healthcare provider of all substances being consumed.


Q: Is there a generic version of Stilus Lapidis available?

The name Stilus Lapidis is a traditional term for the chemical compound Silver Nitrate. As a basic chemical compound, Silver Nitrate is generally available from various producers, often not subject to the same patent restrictions as newer, branded drugs. The product is marketed under the common name 'Silver Nitrate Applicators' or similar terms.


Q: Why does Stilus Lapidis have a warning about driving or operating machinery?

General safety information suggests that Silver Nitrate's localized action means it typically does not affect a person's ability to drive or operate machinery. Warnings in official documents are generally reserved for substances with known systemic central nervous system effects, which are not commonly associated with this topical product.


Q: Is it true that Stilus Lapidis can cause mood changes?

Mood changes or other central nervous system effects are not typically reported in the established safety summaries for topical Silver Nitrate. The primary adverse events documented relate to local reactions and specific systemic conditions, such as gastrointestinal and respiratory issues.


Q: Is there a risk of becoming dependent on Stilus Lapidis?

Official drug classification systems do not categorize the active compound (Silver Nitrate) as having abuse potential or causing dependence. It is not listed as a scheduled substance by regulatory bodies, indicating it does not carry the risk of addiction or physical dependence.


Q: Can Stilus Lapidis cause weight changes (gain or loss)?

Weight changes (either gain or loss) are not listed among the commonly reported or serious adverse events associated with the approved topical use of this product. Adverse event reporting systems focus on documented reactions, and weight changes are not among the effects commonly reported for this product.


Q: Are there any known interactions between Stilus Lapidis and alcohol?

Some safety information states that specific interactions between the topical form of Silver Nitrate and alcohol are not known or have not been established. Official documentation often suggests that any questions regarding consumption of alcohol or interactions should be directed to a healthcare provider.


Q: Does Stilus Lapidis contain any common allergens like gluten or lactose?

The formulation is primarily composed of the active ingredient (Silver Nitrate) and other inorganic components. The product is not generally reported to contain common drug excipients such as gluten or lactose, which are often found in oral medications.


Q: Does Stilus Lapidis affect blood pressure readings?

Adverse events related to changes in blood pressure are not listed among the common or serious side effects of the topical application of this substance. As a topically applied product, it is not listed in regulatory safety summaries as being associated with systemic cardiovascular changes or effects on blood pressure.


Q: Is Stilus Lapidis metabolized by the liver or cleared by the kidneys?

Studies on the fate of silver in the body, which is the active component, show that absorbed silver ions bind to proteins in the blood. They are primarily eliminated through the bile and also through the urine by the kidneys. This absorption is generally considered to be low when the product is applied to intact skin as intended.


Q: Can Stilus Lapidis affect sleep patterns?

Sleep pattern changes or disturbances are not listed as a known or common side effect in official Silver Nitrate product information. This substance is not associated with systemic effects that are typically known to interfere with sleep cycles.


Q: What is the official guidance on managing mild side effects of Stilus Lapidis?

Official drug labels commonly state that if a patient experiences side effects that are bothersome, do not resolve, or if signs of a potential allergic reaction occur, they should seek medical attention. While certain mild, temporary side effects may resolve over time, no specific 'at-home' management instructions are provided in the official documentation.

How should Stilus Lapidis be stored and disposed of?

How to Store and Dispose of Stilus Lapidis?

The storage and disposal requirements for Stilus Lapidis (Silver Nitrate) are officially defined in regulatory documentation to ensure product integrity and public safety.

Mandatory Storage Conditions

Requirement Official Instruction
Temperature & Light Store at room temperature (e.g., 15 - 25 C) and in a dry place protected from light.
Packaging Must be kept in the tightly closed original container, away from heat and chemically reactive materials.
Child Safety KEEP OUT OF REACH OF CHILDREN. The product must be stored securely, restricted to qualified or authorized persons.

Disposal and Handling

Official documents mandate that unused or expired product be handled as Hazardous Waste and disposed of through an approved waste disposal plant in compliance with all local regulations.

Critically, the product must not be allowed to reach the sewage system or enter drains due to its toxicity to aquatic life. Although light exposure may cause the tip to blacken, regulatory information confirms this does not affect the product’s potency.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Stilus Lapidis found in:

A-Z Index: